Literature DB >> 10454261

Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells.

T Ishikawa1, M Kamiyama, H Hisatomi, Y Ichikawa, N Momiyama, Y Hamaguchi, S Hasegawa, T Narita, H Shimada.   

Abstract

Telomerase activity has been reported in cancer cells after treatment with antineoplastic agents. Assessment of telomerase activity could be a valuable tool to measure the reduction of aggression caused by chemotherapy. This study was designed to investigate the significance of telomerase for chemotherapy with respect to Adriamycin (ADM)-resistance. MCF-7 and its ADM-resistant line (AdrR) were treated with ADM, 5-fluorouracil (5FU) or taxotere (TAXO). Telomerase activity and human telomerase RNA component (hTR) were quantitatively measured by the telomeric repeat amplification protocol assay and RT-PCR, respectively. Cell counting and MTT assay were also performed. In MCF-7, enzyme activity was significantly reduced by ADM and 5FU treatments. In AdrR, 5FU and TAXO reduced enzyme activity, while ADM significantly increased the activity. No significant changes in hTR were seen in these two cell lines after treatment with any of these drugs. When Bcl-2 expression was examined after drug treatments, ADM increased Bcl-2 expression in AdrR cells, while not changing it in MCF-7 cells. We conclude that an unusual reaction of telomerase activity in AdrR may explain, at least in part, one of the mechanisms of the malignant biological behavior related with the drug-resistance to ADM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454261     DOI: 10.1016/s0304-3835(99)00103-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Effective inhibition of cancer cell growth by a novel tripartite transfection complex containing ribbon antisense molecules to hTR.

Authors:  Jong-Gu Park
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

2.  A quantitative assay of telomerase activity.

Authors:  Y Gan; J Lu; A Johnson; M G Wientjes; D E Schuller; J L Au
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

3.  Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line.

Authors:  Xiao-Hua Fu; Jian-Song Zhang; Na Zhang; Yang-De Zhang
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

4.  Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells.

Authors:  Jeffrey S Johnston; Andrew Johnson; Yuebo Gan; M Guillaume Wientjes; Jessie L S Au
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

5.  Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer.

Authors:  Lin Wang; Pei-Feng Li; Ming Geng; Yong-Cheng Cao; Ying-Chun Yin
Journal:  Diagn Pathol       Date:  2013-02-22       Impact factor: 2.644

6.  Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study.

Authors:  N Kuranaga; N Shinomiya; H Mochizuki
Journal:  BMC Cancer       Date:  2001-08-01       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.